Clinical trials: Cancer Colorectal
Colorectal Neoplasms Malignant
Effects of COVID-19 Pandemic on the Outcomes of Colorectal Cancer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been identified as the cause of the Coronavirus disease 19 (COVID-19), which was initially reported in December 2019 in China and has since rapidly spread…
- Trial name
- COVID-CRC (NCT04712292)
- Testing
- Surgical procedure for confirmed or suspected colorectal cancer
- Where
- 45 sites in Italy
- Volunteers
- 15,000 people
- Sponsor
- University of Bologna
Metastatic Cancer Rectum
The Role of Short Course of Palliative Radiation in Metastatic Cancer Rectum
Short-course radiotherapy (SCRT), which allows the delivery of 25 Gy in five daily fractions, has emerged as an attractive strategy for rectal cancer treatment.
- Trial name
- NCT06521827
- Testing
- short course radiotherapy
- Volunteers
- 49 people
- Sponsor
- Assiut University
Carcinoma, Midline
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
This study is divided into two parts; Part 1 of the study is a dose escalation phase to select the recommended dose for Part 2 based on the safety, pharmacokinetic, and pharmacodynamic profiles observed after oral administration…
- Trial name
- NCT01587703
- Testing
- GSK525762
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer, Islet Cell Tumor
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Islet Cell Tumor, Liver Cancer, Metastatic Cancer
- Trial name
- NCT00019786
- Testing
- isolated perfusion, melphalan, conventional surgery
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Colorectal Cancer (CRC), Specimens Are to be Collected From Subjects Who Are Having or Have Had a Fluid or Tissue Removed, a Biopsy or a Blood or Bone Marrow Draw
CYFIP1 and PKM2 Synergistically Regulate ROS and Glycolysis in Colorectal Cancer Through the AKT/mTOR/HIF-1α Cascad
Collect some tumor tissue specimens from patients who have undergone colorectal cancer surgery and conduct experiments such as immunohistochemistry to observe the expression of related genes in colorectal cancer.
- Trial name
- NCT07197151
- Testing
- Perform surgery on patients with colorectal cancer and collect cancer and adjacent tissue specimens
- Where
- China
- Volunteers
- 32 people
- Sponsor
- hui hou
Colonic Neoplasms
Establishing Effective Screening Methods for Diagnosing Hereditary Nonpolypoisis Colorectal Cancer
Correct identification of Lynch syndrome at the time of colorectal cancer presentation is important. We aim to find best ways to screen patients with colorectal cancer in Korea.
- Trial name
- NCT00516230
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Colonic Neoplasms, Rectal Neoplasms
Endoscopically Assisted Colostomy With Colopexy for Critically Ill Patients Without General Anesthesia or Laparotomy
Indications for colostomy are rectal or anal cancer, diverticular disease, radiation enteritis, complex perirectal fistulas, anorectal trauma, severe incontinence, motility and functional disorders.
- Conditions
- Colonic Neoplasms, Rectal Neoplasms, Fecal Incontinence
- Trial name
- EACC (NCT02308631)
- Testing
- ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY
- Where
- Brazil
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Colorectal Cancer
Radiation Therapy Before Surgery Compared With Chemotherapy Plus Radiation After Surgery in Treating Patients With Rectal Cancer That Can Be Surgically Removed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003422
- Testing
- fluorouracil, leucovorin calcium, adjuvant therapy
- Where
- 9 sites in Canada, United Kingdom
- Volunteers
- 1,800 people
- Sponsor
- Medical Research Council
Solid Tumor, Colorectal Cancer
MEK and MET Inhibition in Colorectal Cancer
This trial is designed to try two new cancer drugs together for the first time. The investigators think that they might be effective in some types of bowel cancer.
- Trial name
- MErCuRIC1 (NCT02510001)
- Testing
- PF-02341066, PD-0325901, Binimetinib
- Where
- United Kingdom
- Volunteers
- 82 people
- Sponsor
- University of Oxford
Colo-rectal Cancer
Outcomes of Elective Colorectal Cancer Surgery During COVID 19 Pandemic: Implications for Cancer Care Policy
Due to COVID 19 (Corona virus disease)pandemic, majority of surgeries, including surgery for cancer patients got delayed across the globe. Surgeries were limited to emergency set up only.
- Trial name
- NCT04588909
- Testing
- Colorectal resections
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Sheri Kashmir Institute of Medical Sciences
Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm
- Trial name
- NCT02359565
- Testing
- Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Quality Initiative in Rectal Cancer (QIRC) Trial
The Quality initiative in rectal cancer (QIRC) trial will test if a strategy designed to positively influence surgeon practice can decrease hospital rates of permanent colostomy and local tumour recurrence for surgically treated…
- Trial name
- NCT00182130
- Testing
- Quality Initiative in Rectal Cancer (QIRC) strategy
- Volunteers
- 691 people
- Sponsor
- Hamilton Health Sciences Corporation
Colorectal Cancer, Metastatic Cancer
Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Metastatic Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005944
- Testing
- chemotherapy, fluorouracil, leucovorin calcium
- Where
- 18 sites in Belgium, France
- Sponsor
- UNICANCER
Colorectal Cancer
Effects of Reiki Applied to Patients Undergoing Colorectal Cancer Surgery on Postoperative Pain, Anxiety, Physiological Parameters and Recovery
Reiki touch therapy has been used for many years, especially on pain, anxiety and physiological parameters, and studies have been found to show that it is effective.
- Trial name
- NCT07175558
- Testing
- Reiki
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Istanbul University - Cerrahpasa
Lynch Syndrome
Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Patients Meeting Chinese Lynch Syndrome Criteria
The purpose of this study is to find out the proportion of patients diagnosed with Lynch syndrome in colorectal cacner patients meeting Chinese Lynch syndrome criteria.
- Trial name
- NCT03046849
- Testing
- next-generation sequencing
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ewing Sarcoma, Colorectal Adenocarcinoma
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
- Trial name
- NCT03715933
- Testing
- INBRX-109, Irinotecan, Temozolomide
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 411 people
- Sponsor
- Inhibrx Biosciences, Inc
Colorectal Neoplasms
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
After consultation with the Korean Health Authorities, the two Post-Authorization Safety Studies EMR 62202-509 (NCT01082315) and EMR 62241-508 (NCT01075828) were combined within one study protocol EMR 062202-551.
- Trial name
- NCT01082315
- Testing
- Erbitux (Cetuximab)
- Where
- South Korea
- Volunteers
- 730 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lynch Syndrome
Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer
The purpose of this study is to determine the proportion of patients diagnosed with Lynch syndrome in colorectal cancer patients with the loss of staining by immunohistochemistry (IHC) of any of the mismatch repair (MMR)…
- Trial name
- NCT03047226
- Testing
- next-generation sequencing
- Where
- 7 sites in China
- Volunteers
- 311 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Rectal Cancer
Sigmoid Take-off, New Rectum Definition
The diversity of definitions for the rectosigmoid junction is becoming a major obstacle to the standardization of optimal treatment of rectal cancers.
- Trial name
- NCT04293835
- Testing
- Whether to have intestinal-related disease
- Where
- China
- Volunteers
- 835 people
- Sponsor
- Peking University Third Hospital
Advanced or Metastatic Colorectal Cancer (mCRC)
Individual Patient Expanded Access to CA102N
This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.
- Trial name
- NCT05274204
- Testing
- CA102N
- Sponsor
- Holy Stone Healthcare Co., Ltd